Notably, CXCR4 has been extensively studied, and several inhibitors targeting CXCR4, such as AMD3100 (Plerixafor), have been developed and tested in clinical trials, primarily for their role in mobilizing hematopoietic stem cells and in the treatment of cancers like leukemia and breast cancer [94, 95]. Here, CXCR4 is linked to breast cancer.